ALK References

Original References:

1. Hassan B, Akcakanat A, Holder AM, Meric-Bernstam F. Targeting the PI3-kinase/Akt/mTOR signaling pathway. Surg Oncol Clin N Am. 2013;22(4):641-664.
2. Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17-25.
3. Siraj AK, Beg S, Jehan Z, et al. ALK alteration is a frequent event in aggressive breast cancers. Breast Cancer Res. 2015;17:127.
4. Lai AZ, Schrock AB, Erlich RL, et al. Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA. Oncologist. 2017;22(7):774-779.
5. Beltran B, Castillo J, Salas R, et al. ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. J Hematol Oncol. 2009;2:11.
6. Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776-2780.
7. Antonescu CR, Suurmeijer AJ, Zhang L, et al. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement. Am J Surg Pathol. 2015;39(7):957-967.
8. Trigg RM, Turner SD. ALK in Neuroblastoma: Biological and Therapeutic Implications. Cancers (Basel). 2018;10(4):113.
9. Arbour KC, Riely GJ. Diagnosis and Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017;31(1):101-111.

Drug Table References:

1. Genentech, Inc. ALECENSA (alectinib) capsules, for oral use [package insert]. Revised September 2021. www.gene.com/download/pdf/alecensa_prescribing.pdf. Accessed October 24, 2022.
2. Takeda Pharmaceuticals USA, Inc. ALUNBRIG (brigatinib) tablets, for oral use [package insert]. Revised February 2022. www.alunbrig.com/assets/pi.pdf. Accessed October 24, 2022.
3. Pfizer Inc. LORBRENA (lorlatinib) tablets, for oral use [package insert]. Revised March 2021. https://labeling.pfizer.com/ShowLabeling.aspx?id=11140. Accessed October 24, 2022.
4. Pfizer Inc. XALKORI (crizotinib) capsules, for oral use [package insert]. Revised July 2022. https://labeling.pfizer.com/ShowLabeling.aspx?id=676. Accessed October 24, 2022.
5. Novartis Pharmaceuticals Corporation. ZYKADIA (ceritinib) capsules, for oral use; ZYKADIA (ceritinib) tablets, for oral use [package insert]. Revised October 2021. www.novartis.com/us-en/sites/novartis_us/files/zykadia.pdf. Accessed October 24, 2022.
6. Rich Pipeline With Significant Opportunities. Ascentage Pharma. Accessed October 25, 2022. www.ascentagepharma.com/product-candidates/pipeline/?lang=en.
7. Nuvalent Pipeline. Nuvalent. Accessed October 25, 2022. www.nuvalent.com/pipeline/.
8. SAF-189. Fochon Pharmaceuticals. Accessed October 25, 2022. https://fochonpharma.com/what-we-do/saf-189s/.
9. Repotrectinib. Turning Point Therapeutics. Accessed October 25, 2022. www.tptherapeutics.com/corporate/pipeline/repotrectinib.
10. TPX-0131. Turning Point Therapeutics. Accessed October 25, 2022. www.tptherapeutics.com/corporate/pipeline/tpx-0131.
11. Ma Y, Zhao H, Xue J, et al. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. Eur J Cancer. 2022;173:238-249. doi: 10.1016/j.ejca.2022.06.037.
12. Shi Y, Fang J, Hao X, et al. Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. Signal Transduct Target Ther. 2022;7(1):25. doi: 10.1038/s41392-021-00841-8.
13. Product pipeline diagram. Betta Pharmaceuticals. Accessed October 25, 2022. www.bettapharma.com/en.php/Newdrug/projects.
14. Suzhou Zelgen Biopharmaceuticals. Accessed October 25, 2022. www.zelgen.com/en/index.php/chanpinxian/.
15. Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018.; 2018. Available at: www.globenewswire.com/en/news-release/2018/08/30/1563269/0/en/Zai-Lab-Announces-Financial-Results-and-Corporate-Progress-for-the-Six-Months-ended-June-30-2018.html. Accessed October 25, 2022.